RVL Pharmaceuticals

RVL Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is 74.60 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 68.21 % — a change of 9.36% (higher).

FCF Conversion

74.60 %

YoY

9.36%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of RVL Pharmaceuticals is 2022 74.60 % . FCF Conversion Rate (FCF/EBITDA) of RVL Pharmaceuticals was 2021 68.21 % . It decreases by 9.36% higher compared to the previous year.

The RVL Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
145.19 USD
Jan 1, 2017
-112.82 USD
Jan 1, 2018
-30.47 USD
Jan 1, 2019
-10.90 USD
Jan 1, 2020
-16.24 USD
Jan 1, 2021
68.21 USD
Jan 1, 2022
74.60 USD
The RVL Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
74.60 %+9.36%
68.21 %-520.02%
-16.24 %+48.98%
-10.90 %-64.22%
-30.47 %-73.00%
-112.82 %-177.70%
145.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RVL Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of RVL Pharmaceuticals is 74.60 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of RVL Pharmaceuticals changed from 68.21 % to 74.60 %, representing a 9.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s RVL Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals